 SOUTH SAN FRANCISCO, Calif., March 24, 2021 GLOBE NEWSWIRE -- Harpoon Therapeutics, Inc. NASDAQ: HARP, a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is an experienced biotech leader and has served in numerous executive and board roles. 